-
National talks about drugs "should be fully equipped". The top three hospitals are no less than 30%!
Time of Update: 2021-11-14
As the new year of national talks approaches, on November 2, Zhejiang Medical Insurance Bureau issued the "Notice on Implementing the "Dual Channel" Management Mechanism for Drugs in National Medical
-
Announcement of the State Drug Administration on Issuing the "Pharmacological Vigilance Quality Management Standards" (No. 65 of 2021)
Time of Update: 2021-11-14
2. Drug marketing authorization holders and drug registration applicants shall actively prepare for the implementation of the "Pharmacological Vigilance Quality Management Regulations", establish and continuously improve the pharmacovigilance system as required, and standardize the development of pharmacovigilance activities .
-
Tianjing Biological Announces New Chief Financial Officer and Chief Strategy Officer
Time of Update: 2021-11-14
Long Jiang served as the chief financial officer or senior vice president of finance in biomedical companies such as WuXi AppTec Group, WuXi MingMa, Zhenhe Technology, and Si Microbiology, and led a number of important positions.
-
Kangfang Bio-PD-1/VEGF Double Antibody Approved for Phase II Clinical Treatment of Non-Small Cell Lung Cancer
Time of Update: 2021-11-14
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 2, Kangfang Biological announced that the new tumor immunotherapy drug AK112 (PD-1/VEGF bispecific antibody) was approved by CDE, and the development of single-drug or combined chemotherapy neoadjuvant/adjuvant therapy can cut non-small cell lung cancer (NSCLC).
-
[2021 ASH] APG-2575, a selective inhibitor of Bcl-2, was selected for two studies, and the Chinese clinical study showed CR
Time of Update: 2021-11-14
Suzhou, China and Rockville, Maryland, U. S. November 5, 2021/PRNewswire/ Pharmaceutical (6855. HK) announced today that the company has three new drugs under development (oribatinib, APG-2575, APG-1
-
Announcement of the State Drug Administration on Revising the Instructions for Oxaliplatin Preparations (No. 102 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the oxaliplatin preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
-
Announcement of the State Food and Drug Administration on the issuance of 3 supplementary inspection methods including the supplementary inspection method for the pseudo-ginsenoside F11 inspection item in Ginseng Yangrong Pills (202
Time of Update: 2021-11-14
According to the relevant provisions of the "Drug Administration Law of the People's Republic of China" and its implementation regulations, "Supplementary Inspection Method for the F11 Inspection Ite
-
In order to ensure drug supply and stable prices, relevant departments in my country are strengthening the security measures for listed drugs
Time of Update: 2021-11-14
Since 2021, the leading department of the consultation and linkage mechanism for the supply and guarantee of shortage of medicines at the national and provincial levels has worked with relevant units to focus on the implementation of the national shortage of medicines list and the key monitoring list of clinically necessary and easy-to-shortage medicines, and continue to promote the sharing of medicine-related information.
-
The Chinese medicine market is showing steady growth. The industry: facing a good time that has never happened before
Time of Update: 2021-11-14
Promoted by favorable national policies and increasing demand, the market size of the Chinese medicine industry has shown a steady growth trend .
Data show that from 2016 to 2020, the compound annual growth rate of the market size of China's traditional Chinese medicine industry will reach 19.
-
Innovative Chinese medicines welcome the outbreak, and a large number of Class 1 new drugs have been applied for clinical application and marketing
Time of Update: 2021-11-14
Recently, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng received the CDE acceptance for the marketing application of Brainshang Lesheng Granules submitted in the new drug category 1.
-
Announcement of the State Food and Drug Administration on the conversion of four drugs including Shufeng Jiedu capsules into over-the-counter drugs (No. 90 of 2021)
Time of Update: 2021-11-14
The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together .
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
-
Announcement of the State Food and Drug Administration on the Implementation of the Application of Electronic General Technical Documents for Drugs (No. 119 of 2021)
Time of Update: 2021-11-14
The Drug Evaluation Center of the National Medical Products Administration will do a good job in the relevant technical guidance during the implementation of this announcement .
-
Undertake the spillover effect and continue to invest in China, Boehringer Ingelheim participated in the 4th CIIE to practice the concept of "same health"
Time of Update: 2021-11-14
Shanghai, November 2, 2021/PRNewswire/ - At the 4th CIIE, Boehringer Ingelheim, a world-renowned R&D-driven biopharmaceutical company, will bring 500+100 square meters of double booths to fully demonstrate that companies are promoting mankind And innovations in animal health .
-
Announcement of the State Food and Drug Administration on the conversion of Liubo Zhangmin liniment prescription drugs into non-prescription drugs (No. 93 of 2021)
Time of Update: 2021-11-14
Variety non-prescription drug instruction sheet template (82 ml) State Food and Drug Administration July 9, 2021 State Drug Administration Announcement No.
-
[2021 ASH] The clinical progress of Oribatinib, a new anti-drug-resistant leukemia drug, was selected as an oral report at the ASH annual meeting for the fourth time. A total of three studies of this product were selected
Time of Update: 2021-11-14
Oribatinib (HQP1351) is the key to the treatment of tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I mutant chronic myelogenous leukemia (CML-CP and CML-AP) subjects The latest results of the phase II trial 3598 Poster display Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetic (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)
-
National Medical Insurance Administration: In principle, all national drug procurement agreements should continue to carry out centralized procurement after the expiration of the agreement
Time of Update: 2021-11-14
44 The medical insurance bureaus of all provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps: In order to implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" (Guobanfa [2021] No.
-
Announcement of the State Food and Drug Administration on Revising the Insert Sheets of 4 Kinds of Drugs including Cold and Clearing Heat Preparations (No. 88 of 2021)
Time of Update: 2021-11-14
According to the evaluation results of adverse drug reactions, in order to further ensure the safety of the public use of drugs, the National Medical Products Administration has decided to make unified revisions to the four instructions of the cold and heat-clearing preparations [Adverse Reactions], [Contraindications] and [Precautions] .
-
Announcement of the State Food and Drug Administration on the publication of the list of medical pharmacy professional publications that allow the publication of prescription drug advertisements (No. 64 of 2021)
Time of Update: 2021-11-14
According to the "Advertising Law of the People's Republic of China", the National Health Commission of the People's Republic of China agreed to include the "Journal of Alzheimer's Disease and Relate
-
Traditional Chinese medicine decoction pieces are frequently found to be unqualified. How should pharmaceutical companies ensure quality and safety?
Time of Update: 2021-11-14
Therefore, pharmaceutical equipment companies also need to continue to carry out technological innovation, while promoting the high-quality development of traditional Chinese medicine decoction pieces, continuously improve their own competitiveness .
-
What is Pfizer still planning to return to the world's No. 1 mRNA vaccine?
Time of Update: 2021-11-14
In the financial report, Pfizer raised its full-year sales forecast for Comirnaty's new crown vaccine by 7% to approximately US$36 billion .
Pfizer also announced the latest developments in six key R&D pipeline products including the new crown vaccine, gene therapy pipeline, PDE4 inhibitor, TL1A inhibitor, IFN-β inhibitor and oral COVID-19 drugs .
